Trastuzumab deruxtecan + Ramucirumab + Paclitaxel
Phase 3Active 2 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Cancer, Adenocarcinoma
Conditions
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Trial Timeline
May 21, 2021 → Aug 31, 2026
NCT ID
NCT04704934About Trastuzumab deruxtecan + Ramucirumab + Paclitaxel
Trastuzumab deruxtecan + Ramucirumab + Paclitaxel is a phase 3 stage product being developed by Daiichi Sankyo for Gastric Cancer, Adenocarcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT04704934. Target conditions include Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma.
What happened to similar drugs?
5 of 20 similar drugs in Gastric Cancer, Adenocarcinoma were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04704934 | Phase 3 | Active |
Competing Products
20 competing products in Gastric Cancer, Adenocarcinoma